Abstracts

LIVER FIBROSIS CHANGES OVER 3 YEARS OF TENOFOVIR-BASED ART IN HIV-HBV COINFECTION

Although tenofovir-based therapy can potently reduce HBV DNA and can reverse hepatic fibrosis in HBV monoinfection, its long-term impact on clinical outcomes in HIV-HBV coinfection is not well-established and some data suggest hepatic inflammation and fibrosis persists. In Zambian HIV-HBV coinfected adults treated with antiretroviral therapy (ART), we analyzed normalization of ALT and changes in…

LONG-ACTING TENOFOVIR AND NITAZOXANIDE FORMULATIONS SUPPRESS HBV REPLICATION

To eliminate HBV infectious complete suppression of progeny virus coordinate with the elimination of infected cells must be achieved.  These events can be facilitated by enhancing innate and adaptive immune responses given with antiviral therapy. We offer a new therapeutic prospective by increasing  the potency of nitazoxanide (NTZ), a broad-spectrum antiviral and immune stimulating agent and tenofovir (TFV), a nucleoside reverse…

A RHESUS MACAQUE MODEL OF CHRONIC HBV INFECTION FOR CURE RESEARCH

Chronic HBV infection (CHB) is a major global health concern, affecting 247 million individuals worldwide and causing 887,000 deaths annually. CHB induces various degrees of liver damage and is strongly associated with the development of liver cirrhosis and hepatocellular carcinoma. Chimpanzees were the gold standard for primate HBV research, but are no longer available. Indeed,…